Reaching a Phase I, first-in-human (FIH) study is a major milestone for any biotech. It’s also where early decisions start to carry real clinical, regulatory, and commercial consequences.
Having supported a wide range of early clinical programs, one thing becomes clear very quickly: successful Phase I studies are rarely about ticking boxes. They are about clarity of intent, quality of scientific thinking, and early alignment across non-clinical, clinical, and CMC disciplines.
Start with clinical intent — not just a protocol
Before a CRO is selected or a protocol drafted, teams need to be clear on why the drug is being given to humans and what decisions Phase I needs to enable.
That means defining:
- The intended indication and patient population
- Route of administration and dosing frequency
- Target exposure and dose range
- How Phase I data will support later development stages
Build a fit-for-purpose IND-enabling package
There is no shortage of guidance on IND- or CTA-enabling requirements, but more is not always better.
Repeat-dose toxicology, safety pharmacology, genotoxicity (where applicable), and identification of NOAEL or MTD are fundamental, but they should be designed to answer specific questions linked to the intended clinical use.
Early scientific discussion across pharmacology, toxicology, and clinical teams helps ensure the non-clinical package is robust, justified, and aligned with the first-in-human plan without unnecessary studies that add cost and time but little value.
Use PK/PD to turn data into decisions
If toxicology establishes that a drug is safe to test, PK/PD determines how it should be tested.
A well-integrated PK/PD strategy should:
- Define exposure–response relationships
- Link concentration to both pharmacological activity and toxicity
- Support justification of the FIH starting dose
- Inform a rational dose escalation strategy
Programs benefit greatly when pharmacology input is embedded early, allowing animal data to be translated into a clear and defensible human dosing rationale.
CMC readiness should match clinical risk
CMC considerations are often underestimated at the Phase I stage, yet they are central to regulatory confidence and patient safety.
Before entering the clinic, teams need confidence in:
- Drug substance and drug product definition
- Fit-for-purpose formulation and release specifications
- Stability data that support the dosing window
- Appropriate container–closure and handling strategies
At Caidya, a fully-qualified GMP facility embedded within the Clinical Pharmacology Unit allows early clinical development to be approached in an integrated manner, ensuring CMC decisions are aligned with the clinical design and risk profile, rather than treated as a parallel activity.
One size does not fit all in Phase I
Standard SAD/MAD designs provide useful frameworks, but they are not universally appropriate.
Molecule type, mechanism of action, modality, and therapeutic area should all influence study design. The most effective Phase I programs are those where scientific rationale outweighs precedent, and where teams are comfortable adapting approaches to suit the asset.
This requires CRO partners who are willing to challenge assumptions and tailor designs, not simply repeat what has been done before.
Early engagement reduces risk
Early engagement with Regulatory Authorities through Scientific Advice can significantly de-risk development plans. Equally, early collaboration with experienced CRO partners allows strategy to be shaped collaboratively, rather than retrospectively.
With access to experienced pharmacology, clinical, and advisory expertise, potential issues can be anticipated early, helping biotechs focus resources on generating meaningful first-in-human data as efficiently as possible.
Choosing partners, not just providers
Phase I is where a drug first meets human biology. The quality of thinking behind that moment matters.
When selecting a Phase I unit or CRO, biotechs should look beyond facilities and timelines. The most productive relationships are partnerships built on scientific dialogue, experience, and a shared understanding of what success looks like, not just for Phase I, but for the program as a whole.
At Caidya, our focus on early clinical development, integrated scientific expertise, and tailored Phase I design allows us to support biotechs through this critical transition, from preclinical promise to meaningful first-in-human data.